Melanoma (Screening)

Techtide Trial Commenced To Detect Melanoma Spread

Published in Cancer Weekly, October 28th, 1996

Diatide, Inc., Londonderry, New Hampshire, has begun Phase III clinical trials of the safety and efficacy of P829 Techtide in detecting metastasis of malignant melanoma.

P829 is a unique combination of a synthetic peptide designed to attach to targeted diseased tissues and technetium-99m, a radioactive material detected by the gamma cameras now used by hospitals throughout the U.S. and in other parts of the world. P829 is expected to be more accurate and significantly less expensive than computerized tomography, the primary procedure currently used to identify melanoma, neuroendocrine, breast and lung tumors.

The first of the 260 patients enrolled...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry